+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06769698

Randomized Study Comparing Fianlimab Plus Cemiplimab With Cemiplimab and Placebo for First-Line Treatment of Recurrent or Metastatic PD-L1 Positive Head and Neck Squamous Cell Carcinoma

Led by Regeneron Pharmaceuticals · Updated on 2026-10-22

120

Participants Needed

38

Research Sites

133 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of combining an experimental drug called fianlimab REGN3767 with cemiplimab, compared to cemiplimab with a placebo, in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC that has not been previously treated. The study focuses on patients whose cancer is positive for PD-L1 expression and aims to understand side effects, drug levels in the blood, and immune responses to the treatments. Participants are divided into two groups based on HPV status one with HPV-positive HNSCC and the other with HPV-negative HNSCC. Each group is randomly assigned to receive either the combination of fianlimab and cemiplimab or cemiplimab with placebo. Both treatments are given as fixed-dose combinations according to the study protocol. During the study, participants will be monitored for up to about 58 months, including assessments of overall response rate, disease control, progression-free survival, and duration of response. Researchers will also track various types of adverse events and measure drug concentrations and antibody responses in the blood. Safety and treatment effects will be evaluated throughout and up to 90 days after the last treatment dose.

CONDITIONS

Brief Title

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here